The following examples provide an indication of the usefulness of this model in preclinical drug development.
1. DETERMINATION OF IN VIVO EFFICACY.
2. IDENTIFICATION OF METABOLIC LIABILITIES.
3. OPTIMISATION OF CLINICAL DOSING REGIMEN.
4. INVESTIGATION OF TOXICOKINETICS.
© Copyright CXR Biosciences Scotland 2007 | James Lindsay Place, Dundee Technopole, Dundee, Scotland DD1 5JJ Tel +44 1382 432163 Web Design, Development and hosting by MTC Media
